GMK Sphere TiNb Total Knee Arthroplasty PMS Study

Last updated: April 30, 2024
Sponsor: Medacta International SA
Overall Status: Active - Recruiting

Phase

N/A

Condition

Knee Replacement

Treatment

blood sample

Clinical Study ID

NCT04801654
P.02.01.427
  • Ages > 18
  • All Genders

Study Summary

Total knee arthroplasty (TKA) is one of the success stories of modern surgery, providing high patient satisfaction outcomes. Total knee prostheses are generally composed by a femoral component articulating on a polyethylene insert and a tibial tray.

Recently there has been particular attention on the component material; traditionally femoral components are made of cobalt alloys while tibial baseplates are made, in the great majority of cases, of metallic materials, but also polyethylene versions are available. There has been a degree of acceptance in some countries that metal related pathology may exist as demonstrated by the Australian Arthroplasty register where metal hypersensitivity was reported as the fifth most common cause for revision hip arthroplasty 2012 report, making up for 5.9% of all revisions. The wording was subsequently changed from "metal sensitivity" to "metal related pathology" in the 2014 report with 0.5% of all revision total hip arthroplasties (THA) associated with this term. The same change in terminology was used for TKA with metal sensitivity as a cause for revision in 1.3% of revisions in 2012 and in 2014, 1.8% of revision TKAs attributed to "metal related pathology" . The overall revision rate was 3.45% after 10 years in 396.472 TKAs, suggesting a revision rate of 0.06-0.32% secondary to metal or cement allergies. Up to today there is no question that metallic implants may generate wear debris that cause local reactions. This local reaction is not dose related nor predictable and therefore not purely due to the toxic effect of the debris but possibly due to an immunological host process. Hypersensitivity to metal undoubtedly exists but it cannot be stated at the moment to be an allergic reaction. To prevent issues arising due to metal related pathology, alternative solutions to conventional chrome cobalt material have been proposed, for example ceramic component or implant coating. In particular, TiNbN coating has been proposed by most companies thanks to its excellent biological properties. Preclinical studies have showed a high scratch resistance and low coefficient of friction, more resistance to fretting corrosion, reduction of wear, lower ion release rates and low fatigue cycle, as described in the review of Hove. Clinically, cohort of studies of TiN-coated implants showed an overall survival exceeding 90% with a follow-up of 15 to 77 months and good clinical outcomes. No reports of adverse effects related to TiN coating of CoCrMo knee implants have been showed. There are few studies that compared TiN-coated implants with the same uncoated version. Thienpont, comparing TiN-coated and uncoated CoCrMo implants, showed similar clinical and radiological outcomes at short-term follow up in both patients groups .

Overall we can conclude that in literature no adverse events have been reported concerning the TiNbN coating and in particular it has been showed that the coating doesn't not affect the performance of the device if compared with the same uncoated version.

The aim of this study is to evaluate the long term clinical and radiological performance of GMK Sphere total knee component, coated version.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Those older than 18 years old at the surgery time
  • those suitable to undergo to a primary total knee arthroplasty for whom the GMK SphereTiNb coated device will be implanted (according to the labelindication/contraindications)
  • Patients who are willing and able to provide written informed consent forparticipation in the study. Written informed consent must be obtained prior topatient's surgery

Exclusion

Exclusion Criteria:

  • Those patients with metal implants containing Co, Cr and / or Ni
  • Those patients who have had environmental or occupational exposure to toxic metalssuch as Co, Cr and / or Ni (solvents, industrial paints, welders)
  • Those whose mental conditions may compromise their ability to provide informed consentto study participation, ability to complete questionnaires or complete 10-yearfollow-ups
  • Those unable to give their consent to participate in the study or who do not want toparticipate
  • Any condition not mentioned in inclusion criteria.

Study Design

Total Participants: 155
Treatment Group(s): 1
Primary Treatment: blood sample
Phase:
Study Start date:
February 05, 2020
Estimated Completion Date:
December 05, 2033

Connect with a study center

  • IRCCS Istituto Ortopedico Galeazzi di Milano Sede di via Monreale18 (Istituto Clinico San Siro)

    Milan, MI 20148
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.